A simple sugar the body uses to build the molecule cells rely on for energy. The strongest human result is a controlled study easing symptoms in a stiff-heart form of heart failure; fatigue and soreness signals rest on very small or uncontrolled studies, and it has not improved athletic performance. A long-term safety question over sugar-protein damage stays unresolved. (Full Review)

Protocol

Standard Dose

15 g/day

Heart-failure trial dose for 12 weeks, add-on to standard therapy; chronic-fatigue use was 5 g three times daily

Dosing Strategy

Split with food

Short plasma half-life (tens of minutes); divide the daily amount, and start low (5 g/day) titrating up to limit side effects

Timing

Tied to need

Divided through the day in clinical use; before and at intervals after exercise in recovery protocols

Time to effect

Heart-Failure Symptoms

12 weeks

Symptom changes measured over the controlled trial horizon

Exercise Recovery

Hours to days

Recovery effects assessed around exercise; no benefit is immediate or dramatic

Benefits

Medium: Symptom relief in heart failure with preserved ejection fraction

Low: Reduced post-exercise muscle soreness and damage; symptom improvement in chronic fatigue and fibromyalgia

Speculative: Improved exercise tolerance in coronary artery disease; general energy, vitality, and recovery in healthy adults

Contraindications

Pregnancy and breastfeeding

Hereditary fructose intolerance or other rare sugar-metabolism disorders

Scheduled surgery (discontinue ~2 weeks before)

Key Interactions

Glucose-lowering drugs (insulin, sulfonylureas such as glipizide, meglitinides)

High-dose aspirin and some over-the-counter agents

Blood-sugar-lowering supplements (chromium, berberine, alpha-lipoic acid, cinnamon extract)

Risk & Side Effects

Medium: Hypoglycemia and blood-sugar lowering

Low: Gastrointestinal upset

Speculative: Advanced glycation end product (AGE) formation; possible link to glucose dysregulation; uric acid elevation

Monitoring

Marker	Target	Why
Fasting blood glucose	75–90 mg/dL	Detects ribose's blood-sugar-lowering effect, especially with diabetes drugs
HbA1c	< 5.4%	Tracks longer-term glycemic effect and the theoretical glycation concern
Natriuretic peptide	Below assay's age-adjusted cutoff	In heart-failure use, tracks cardiac strain that fell in the controlled trial
Uric acid	3.5–6.0 mg/dL (lower within range for gout-prone)	Addresses the theoretical purine/uric-acid concern

Cadence: Fasting glucose at baseline and within the first 1–2 weeks of starting or dose escalation in anyone with diabetes or on glucose-lowering drugs, then every 3–6 months with continued use; cardiac status tracked over weeks-to-months in heart-failure use

Qualitative Assessment

Subjective energy and fatigue levels through the day
Exercise recovery and next-day muscle soreness after hard sessions
Sleep quality and daytime mental clarity
In heart-failure use, breathlessness and exercise tolerance in daily activities

D-Ribose for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment